Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR4 | P51679 | 16/20 | 0.39 |
| ▸ | CCR5 | P51681 | 1/20 | 0.36 |
| ▸ | EDNRA | P25101 | 4/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21274185 | 0.85 | CCR4 (0.42) | CCR4CCR5EDNRA | |
| SCHEMBL29862869 | 0.85 | CCR4 (0.42) | CCR4CCR5EDNRA | |
| SCHEMBL1476090 | 0.79 | CCR4 (0.36) | CCR4EDNRA | |
| SCHEMBL29956405 | 0.79 | CCR4 (0.36) | CCR4EDNRA | |
| SCHEMBL1474362 | 0.78 | CCR4 (0.37) | CCR4 | |
| SCHEMBL30416654 | 0.76 | CCR4 (0.45) | CCR4CCR5EDNRA | |
| SCHEMBL609085 | 0.76 | CCR4 (0.45) | CCR4CCR5EDNRA | |
| SCHEMBL30995255 | 0.74 | TRIM24 (0.33) | — | |
| SCHEMBL29749999 | 0.74 | CCR4 (0.41) | CCR4CCR5EDNRA | |
| SCHEMBL376592 | 0.74 | CCR4 (0.41) | CCR4CCR5EDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114630822-B | Biaryl dihydroorotate acid dehydrogenase inhibitors | 詹森生物科技公司 | 2024-10-01 | — | — | CN | disclosed |
| US-20240158414-A1 | BI-ARYL DIHYDROOROTATE DEHYDROGENASE INHIBITORS | JANSSEN BIOTECH, INC. | 2024-05-16 | — | — | US | disclosed |
| EP-4041714-B1 | BI-ARYL DIHYDROOROTATE DEHYDROGENASE INHIBITORS | JANSSEN BIOTECH INC (US) | 2023-12-13 | — | — | EP | disclosed |
| EP-4041714-A1 | BI-ARYL DIHYDROOROTATE DEHYDROGENASE INHIBITORS | Janssen Biotech, Inc. (US) | 2022-08-17 | — | — | EP | disclosed |
| CN-114630822-A | Biaryl dihydroorotate dehydrogenase inhibitors | 詹森生物科技公司 | 2022-06-14 | — | — | CN | disclosed |
| WO-2021070132-A1 | BI-ARYL DIHYDROOROTATE DEHYDROGENASE INHIBITORS | JANSSEN BIOTECH, INC. (US) | 2021-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158414-A1 | BI-ARYL DIHYDROOROTATE DEHYDROGENASE INHIBITORS | DHODH, DLD, DPYD | CCR4 4397/4885CCR5 4524/4885EDNRA 2247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.